Clinical trials: Breast Lobular Carcinoma In Situ
DCIS
Prospective Evaluation of Breast-Conserving Surgery Alone in Low-Risk Ductal Carcinoma in Situ (DCIS)
To evaluate whether the combination of clinicopathological factors and the use of the Oncotype DX DCIS score can avoid radiation in women with low risk DCIS who have had breast conserving surgery (BCS)
- Trial name
- ELISA (NCT04797299)
- Where
- 24 sites in Canada
- Volunteers
- 526 people
- Sponsor
- Ontario Clinical Oncology Group (OCOG)
Breast Reconstruction, Ductal Carcinoma In-situ
Study to Assess Breast Sensation Before and After Breast Cancer Treatment
The purpose of this study is to establish techniques for evaluating breast cutaneous sensation at baseline and following either lumpectomy or mastectomy for breast cancer.
- Trial name
- NCT02817607
- Testing
- Sensory testing and Biopsy
- Where
- United States
- Sponsor
- Duke University
Anxiety Disorder, Breast Cancer
Measuring Stress in Women With Newly Diagnosed Stage I, Stage II, or Stage III Breast Cancer or Ductal Carcinoma In Situ of the Breast
RATIONALE: Gathering information about how patients respond to stress and measuring stress levels in women with newly diagnosed breast cancer may help doctors provide better methods of treatment and on-going care.
- Conditions
- Anxiety Disorder, Breast Cancer, Depression, Psychosocial Effects of Cancer and Its Treatment
- Trial name
- NCT00665782
- Testing
- laboratory biomarker analysis, questionnaire administration, study of socioeconomic and demographic variables
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Wake Forest University Health Sciences
Breast Cancer, Dermatologic Complications
Mometasone Furoate in Preventing Radiation Dermatitis in Patients Undergoing Radiation Therapy to the Breast or Chest Wall for Invasive Breast Cancer or Ductal Carcinoma in Situ
RATIONALE: Steroid therapy, such as mometasone furoate, may prevent radiation dermatitis caused by radiation therapy. It is not yet known whether mometasone furoate is more effective than a placebo in preventing radiation…
- Conditions
- Breast Cancer, Dermatologic Complications, Radiation Toxicity, Skin Reactions Secondary to Radiation Therapy
- Trial name
- NCT00438659
- Testing
- mometasone furoate
- Where
- 189 sites in United States
- Volunteers
- 176 people
- Sponsor
- North Central Cancer Treatment Group
Breast Neoplasms
Intra-operative Radiotherapy For Breast Cancer Women After NSM
The role of NSM is still controversial, mainly because of concern about the oncologic safety of the nipple-areola complex (NAC).INTRABEAM (Carl Zeiss, Oberkochen, Germany) is the most widely used mobile intraoperative…
- Trial name
- NCT02389686
- Testing
- INTRABEAM (Carl Zeiss, Oberkochen, Germany)
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Liao Ning
Breast Cancer, Lobular Carcinoma
Molecular Genetic Basis of Invasive Breast Cancer Risk Associated With Lobular Carcinoma in Situ
This study is being done in order to better understand the biology of an abnormal lesion found in breast tissue called "lobular carcinoma in situ" (LCIS). We are interested in studying LCIS.
- Conditions
- Breast Cancer, Lobular Carcinoma, Invasive Breast Cancer
- Trial name
- NCT00581750
- Testing
- Tissue specimen
- Where
- United States
- Volunteers
- 550 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Ductal Carcinomas
MRI in Ductal Carcinoma in Situ (DCIS)
Compare the estimate of the lesional size in MRI to that in mammography, taking as a reference the definitive anatomo-pathological size
- Trial name
- NCT03543397
- Where
- France
- Volunteers
- 74 people
- Sponsor
- University Hospital, Strasbourg, France
Breast Cancer, Osteoporosis
Risedronate in Improving Bone Mineral Density and Bone Health in Postmenopausal Women With Ductal Carcinoma In Situ Enrolled in Clinical Trial CRUK-IBIS-II-DCIS
RATIONALE: Bisphosphonates, such as risedronate, may help improve bone health and prevent osteoporosis in postmenopausal women. It is not yet known whether risedronate is effective in improving bone mineral density and bone…
- Trial name
- NCT00324714
- Testing
- risedronate sodium, diagnostic laboratory biomarker analysis
- Where
- 2 sites in Switzerland
- Sponsor
- ETOP IBCSG Partners Foundation
Anxiety Disorder, Depression
Educational Counseling in Improving Communication and Quality of Life in Spouses and Breast Cancer Patients
This randomized clinical trial studies educational counseling in improving communication and quality of life in spouses and breast cancer patients.
- Conditions
- Anxiety Disorder, Depression, Ductal Breast Carcinoma in Situ, Lobular Breast Carcinoma in Situ
- Trial name
- NCT01723943
- Testing
- educational intervention, counseling intervention, psychosocial support for caregiver
- Where
- United States
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- University of Washington
Ductal Breast Carcinoma In Situ, Stage IA Breast Cancer
Extent of Breast Cancer and the Role of Pre-Operative Sonography and MRI
This clinical trial studies mammography and targeted ultrasound with or without whole-breast ultrasound or contrast-enhanced magnetic resonance imaging (MRI) in finding out the extent of disease before surgery in patients with…
- Conditions
- Ductal Breast Carcinoma In Situ, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer
- Trial name
- NCT02587663
- Testing
- Contrast-enhanced Magnetic Resonance Imaging, Mammography, Therapeutic Conventional Surgery
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- University of Southern California
Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer
This randomized phase III clinical trial studies how well tamoxifen citrate, anastrozole, letrozole, or exemestane with or without chemotherapy work in treating patients with breast cancer that has spread from where it began in…
- Conditions
- Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma, Multicentric Breast Carcinoma, Multifocal Breast Carcinoma
- Trial name
- NCT01272037
- Testing
- Anastrozole, Exemestane, Laboratory Biomarker Analysis
- Where
- 1,568 sites in United States, Canada and 8 more
- Volunteers
- 5,018 people
- Sponsor
- National Cancer Institute (NCI)
Breast Ductal Carcinoma In Situ, COVID-19 Infection
Impact of COVID-19 Pandemic on Out-of-Pocket Costs, Lost Wages, and Unemployment in Patients With Breast Cancer Undergoing Breast Surgery
This study investigates the impact of COVID-19 pandemic on out-of-pocket costs, lost wages, and unemployment in patients with breast cancer undergoing breast surgery.
- Conditions
- Breast Ductal Carcinoma In Situ, COVID-19 Infection, Hereditary Breast Carcinoma, Invasive Breast Carcinoma
- Trial name
- NCT04169542
- Testing
- Questionnaire Administration
- Where
- 4 sites in United States
- Volunteers
- 600 people
- Sponsor
- M.D. Anderson Cancer Center
Ductal Carcinoma in Situ
Subzero and Scorpion Trial
This is a prospective single-institution pilot study examining the feasibility of performing ultrasound-guided cryoablation to completely ablate breast ductal carcinoma in situ (DCIS).
- Trial name
- NCT05032079
- Testing
- cryoablation
- Where
- 2 sites in United States
- Sponsor
- Larkin Community Hospital
Breast Cancer
Tamoxifen Compared With LY353381 in Treating Women With Newly Diagnosed Breast Cancer
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using tamoxifen or LY353381 may fight breast cancer by blocking the use of estrogen.
- Trial name
- NCT00005886
- Testing
- arzoxifene hydrochloride, tamoxifen citrate
- Where
- 9 sites in United States
- Sponsor
- University of Kansas Medical Center
Invasive Breast Cancer, Ductal Carcinoma in Situ
Preoperative Testing of the Anti-Progesterone Mifepristone in Early Stage Breast Cancer
The primary objective of this study is to identify the group of women with early stage breast cancer most likely to benefit from treatment with the selective progesterone receptor modulator (SPRM) mifepristone.
- Trial name
- NCT01138553
- Testing
- Mifepristone
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of California, San Diego
DCIS
Impact of Radiation Therapy on Breast Conservation in DCIS
Large regional variation exists in the use of radiotherapy after breast-conserving surgery (BCS) for ductal carcinoma in situ (DCIS).
- Trial name
- NCT02248662
- Where
- 4 sites in United States
- Volunteers
- 3,436 people
- Sponsor
- Dana-Farber Cancer Institute
Breast Cancer
RAPID: Randomized Trial of Accelerated Partial Breast Irradiation
To determine if Accelerated Partial Breast Irradiation, using 3D CRT, is as effective as Whole Breast Irradiation following breast conserving surgery in women with an new histological diagnosis of ductal carcinoma in situ only or…
- Trial name
- NCT00282035
- Testing
- APBI utilizing 3D-CRT radiation, Whole breast irradiation
- Where
- 33 sites in Australia, Canada and 1 more
- Volunteers
- 2,135 people
- Sponsor
- Ontario Clinical Oncology Group (OCOG)
Breast Cancer
Study of Urine Samples From Women With Newly Diagnosed Breast Cancer Enrolled on Clinical Trial UNMC-08105
RATIONALE: Studying samples of urine from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00959244
- Testing
- high performance liquid chromatography, laboratory biomarker analysis, mass spectrometry
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Nebraska
Primary Invasive Malignant Neoplasm of Female Breast, Carcinoma Breast
Study of AVB-620 in Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery
Phase 2, open-label study of AVB-620 in women with primary, nonrecurrent and nonmetastatic breast cancer undergoing surgery.
- Conditions
- Primary Invasive Malignant Neoplasm of Female Breast, Carcinoma Breast, Breast Cancer Female, Carcinoma, Ductal, Breast
- Trial name
- NCT03113825
- Testing
- Investigational Imaging device, AVB-620
- Where
- 13 sites in United States
- Volunteers
- 92 people
- Sponsor
- Avelas Biosciences, Inc.
Ductal Carcinoma In Situ
Comparative Effectiveness of Sentinel Lymph Node Biopsy for Ductal Carcinoma In Situ
Patients with ductal carcinoma in situ (DCIS) treated with available therapies have experienced excellent outcomes and very low mortality rates due to the disease's non-invasive nature.
- Trial name
- NCT02908178
- Testing
- Sentinel lymph node biopsy (SLNB)
- Where
- United States
- Volunteers
- 28,291 people
- Sponsor
- Yale University